Dizhe Medicine: Revenue is expected to increase by 122.6% to 801 million yuan by 2025, with a competitive pipeline including 7 products already established.

Recently, Dizhi Pharmaceutical released its 2025 annual report. In 2025, the company’s operating revenue was RMB 801 million, representing a year-on-year increase of 122.6%. The net profit attributable to shareholders narrowed its loss from RMB 846 million in the same period last year to a loss of RMB 764 million; the amount of loss decreased. The non-GAAP net profit attributable to shareholders narrowed its loss from RMB 899 million in the same period last year to a loss of RMB 842 million; the amount of loss decreased. Net cash flow from operating activities was -RMB 588 million, up 9.6% year over year. EPS (fully diluted) was -RMB 1.6567.

Among them, in the fourth quarter, the company’s operating revenue was RMB 215 million, representing a year-on-year increase of 901.6%. The net profit attributable to shareholders narrowed its loss from RMB 287 million in the same period last year to a loss of RMB 184 million; the amount of loss decreased. The non-GAAP net profit attributable to shareholders narrowed its loss from RMB 299 million in the same period last year to a loss of RMB 211 million; the amount of loss decreased. EPS was -RMB 0.3992.

As of the end of the fourth quarter, the company’s total assets were RMB 3.003 billion, up 74.7% from the end of the previous year. The net assets attributable to shareholders were RMB 1.294 billion, up 567.8% from the end of the previous year.

In the company’s 2025 annual disclosure, it mentioned that during the reporting period, its business operations experienced significant changes. Two drugs—Shuwozhe® and Gaurize®—that had already been successfully launched were first included in the National Reimbursement Drug List, and in July 2025, they obtained accelerated approval for market entry from the FDA, becoming the only targeted drugs in the world with approvals in both the U.S. and China for EGFR exon20ins-positive non-small cell lung cancer in the second-line or later setting that are also reimbursable. These changes have significantly enhanced the company’s market competitiveness and sales revenue.

In addition, the company completed refinancing during the reporting period, providing key support for high-quality development. Although the company made progress in drug sales, it still needs to continuously advance the expansion of product indications and the development of subsequent pipeline candidates. By the end of the reporting period, the company was not yet profitable, and it has accumulated unaddressed losses.

(Dizhi Pharmaceutical announcement)

(Editor: Yang Yan, Lin Chen)

Key words:

                                                            Healthcare